Issuer Credit Research
Issuer Flash: Nan Shan Life Insurance
Issuer: Nan Shan Life Insurance | Document: Issuer Flash | Date: 2026-08-28 | Event: Q2 1h 2026 Results
Report date: 2026-08-28 Event date: 2026-08-26 Event title: Q2 / H1 2026 results under IFRS 17
1. Flash Conclusion
Nan Shan Life Insurance's H1 2026 consolidated financial statements strengthen the supportive direction seen in the Q1 flash, but they do not resolve the core FX, asset-liability-management (ALM), liquidity or regulatory-capital questions identified in the May issuer summary. H1 net profit was NT$30.9bn, compared with a restated NT$54.4bn loss in H1 2025, while reported equity rose to NT$563.0bn at 30 June 2026 from restated NT$288.6bn at end-2025. Issued-contract CSM also increased to NT$392.8bn from NT$374.8bn at the start of 2026. Those are meaningful positive data points for an insurer whose earnings and capital presentation had been volatile through the IFRS 17 / IFRS 9 transition.
For bondholders, however, the result is better viewed as confirmation of improved reported profitability and balance-sheet resilience than as a clean improvement in economic risk. The H1 result included NT$238.7bn of after-tax other comprehensive income (OCI), financial-result performance remains market-sensitive, cash and cash equivalents fell to NT$120.0bn from NT$279.6bn at end-2025, and operating cash flow was negative. The official report confirms compliance with applicable capital-adequacy and net-worth requirements in each of the latest two periods, but it does not provide numerical ICS ratios, a detailed hedge-cost analysis, asset-liability duration data, liability currency composition, surrender metrics or rating-agency capital measures. The existing view therefore remains: a large Taiwan life-insurance franchise with supportive current results, constrained by material sensitivity to FX, interest rates, market values and long-duration policyholder liabilities.
2. What Was Announced
The issuer published consolidated financial statements and an independent auditors' report for the six months ended 30 June 2026. As in the Q1 report, 2026 is the first year in which the company's reporting applies the IFRS 17 insurance-contract and related IFRS 9 financial-asset framework; the report presents restated 2025 comparatives. The comparison in this flash uses those restated figures rather than data under the prior presentation.
The insurance service result was broadly stable: NT$17.5bn in H1 2026, against restated H1 2025 NT$17.7bn. The change in headline profitability was instead driven by the financial result, which was positive NT$33.4bn after a restated NT$102.5bn loss a year earlier. Net profit was NT$30.9bn and total comprehensive income was NT$269.6bn, compared with a net loss of NT$54.4bn and a comprehensive loss of NT$98.6bn in the restated comparator.
At end-June, consolidated assets were NT$5.776tn and insurance-contract liabilities were NT$4.481tn, down from NT$4.584tn at end-2025. Equity reached NT$563.0bn. FVOCI financial assets were NT$1.294tn at end-June versus NT$273.7bn at end-2025, while FVTPL financial assets were NT$284.4bn versus NT$898.0bn. The available disclosure does not provide enough reconciliation of classification, transactions, valuation or resulting economic exposure to infer a portfolio de-risking from those two balance changes; accounting presentation should not be equated with a fully de-risked economic profile.
3. Credit Read-Through
The positive H1 earnings provide a second, more substantial check on the Q1 conclusion that the March monthly loss should not be treated as evidence of persistent weakness. The insurance-service result was close to the restated prior-year level, while the financial result moved sharply positive. This supports the view that the issuer's underlying franchise continues to generate an insurance-service contribution, but it also shows that total earnings remain heavily influenced by investment, interest-rate, FX and insurance-finance effects. The report's H1 foreign-exchange gain of NT$17.2bn and its NT$13.6bn net change in the FX valuation reserve illustrate why earnings should not be reduced to a simple underwriting trend.
Capital presentation improved substantially. Equity rose by NT$274.4bn from end-2025, supported by H1 profit and OCI. In addition, the CSM balance rose by NT$17.9bn to NT$392.8bn, after NT$13.8bn was recognised in profit for insurance services transferred during the half year. The direction is supportive because CSM represents unearned profit to be recognised as future insurance services are provided. It is not a substitute for solvency analysis: the report states that the businesses met applicable capital-adequacy and net-worth requirements, but it provides no numerical ICS ratio or buffer. The company also describes liability measurement as sensitive to assumptions including mortality, morbidity, lapse behaviour, expenses, discount rates and financial guarantees. Consequently, the current disclosure does not establish that capital headroom is robust under adverse FX, rate, spread or policyholder-behaviour stresses.
Liquidity and funding merit continued attention. Cash and cash equivalents declined by NT$159.6bn during H1, and operating cash flow was negative NT$136.6bn. The cash-flow statement also shows NT$25.0bn of bond repayments, NT$9.1bn of bond issuance and NT$20.1bn of net financing outflow. These figures do not by themselves demonstrate a liquidity shortfall: a life insurer's cash flows must be read alongside investment-portfolio liquidity, policyholder behaviour, collateral and hedge needs, and the timing of insurance cash flows. Still, they make it important to obtain the missing detail before drawing a stronger liquidity conclusion. Bonds payable fell to NT$110.7bn from NT$126.0bn at end-2025, which is modestly supportive for reported debt, but Tier 2 investors retain the instrument-specific subordination, coupon and loss-absorption risks identified in the issuer summary.
4. Key Numbers
All figures are consolidated and in NT$bn unless otherwise stated.
| Metric | H1 / 30 Jun 2026 | Restated H1 / 30 Jun 2025 or end-2025 comparator | Credit reading |
|---|---|---|---|
| Insurance service result | 17.5 | 17.7 (H1 2025) | Stable service contribution, but not the source of the large headline swing. |
| Financial result | 33.4 | (102.5) (H1 2025) | Recovery is supportive but remains market- and FX-sensitive. |
| Net profit | 30.9 | (54.4) (H1 2025) | Positive reversal from the restated prior-year loss. |
| Total comprehensive income | 269.6 | (98.6) (H1 2025) | Large OCI contribution means reported equity is valuation-sensitive. |
| Total equity | 563.0 | 288.6 (end-2025) | Materially stronger presented equity; numerical ICS headroom is not disclosed. |
| Insurance-contract liabilities | 4,480.7 | 4,583.8 (end-2025) | Remain the central ALM and policyholder-liability exposure. |
| Issued-contract CSM | 392.8 | 374.8 (start-2026) | Supports future service-profit visibility, subject to assumption and financial-risk sensitivity. |
| Cash and cash equivalents | 120.0 | 279.6 (end-2025) | Requires follow-up with portfolio-liquidity and surrender data. |
| Bonds payable | 110.7 | 126.0 (end-2025) | Reported balance declined after net H1 repayments. |
Source: Nan Shan Life H1 2026 consolidated financial statements; 2025 comparatives are restated where indicated.
5. What To Watch Next
- Obtain the numerical ICS capital-adequacy ratio, net-worth ratio, capital buffer and any rating-agency assessment after the H1 disclosure; compliance alone is not enough to judge resilience under stress.
- Track the next official quarterly financial report for whether the H1 earnings, equity and CSM direction persists after market, FX and hedge-cost effects.
- Recheck cash, operating cash flow, investment-portfolio liquidity, collateral and surrender experience before treating the H1 cash decline as either benign or adverse.
- Seek the currency composition of assets and insurance liabilities, ALM duration gap, hedge cost, guaranteed-rate exposure, lapse / surrender data, claims experience and product-level profitability.
- For any Tier 2 investment decision, obtain the offering circular and trust deed to assess ranking, coupon restrictions, loss absorption, calls and redemption approvals separately from the issuer-level results.
6. Sources
- Nan Shan Life Insurance Company, Ltd. and subsidiaries, Consolidated Financial Statements and Independent Auditors' Report, H1 2026, official issuer PDF, 26 August 2026,
https://www.nanshanlife.com.tw/nanshanlife/portal-api/File/11654. Used for all new financial and capital-management facts in this flash. - Nan Shan Life, Financial Reports page, accessed 28 August 2026,
https://www.nanshanlife.com.tw/nanshanlife/investor-relations-financialinfo-report/. Used to confirm the official Q2 report publication route. issuer_summary/issuers/nan_shan_life_insurance/current/nan_shan_life_insurance_issuer_summary_20260514.mdandissuer_summary/issuers/nan_shan_life_insurance/current/nan_shan_life_insurance_issuer_flash_q1_2026_results_20260623.md. Used solely for the prior internal credit view and comparison context.